Glucose Transporter 4 and Peroxisome Proliferator-Activated Receptor-Alpha Overexpression Association With Cardioprotective Effects of Myoinositol and Metformin Combination in Type 2 Diabetic Rat Model

Background: Type 2 diabetes mellitus (DM) has many complications associated with increased morbidity and mortality. Cardiovascular are one of these serious complications. Therefore, there is a need for early effective management to hamper them. This study aimed evaluate the cardioprotective efficacy metformin myoinositol combination through exploring underlying mechanisms in type DM rat model. Methods: model was induced rats by streptozotocin high-fat diet. Rats were treated (150 mg/kg) and/or (50 oral gavage once daily 4 weeks. Immunohistochemistry used assess drugs’ estimating troponin T, nuclear factor kappa B (NF-kappaB) tumor necrosis alpha (TNF-alpha). Quantitative real-time polymerase chain reaction enzyme-linked immunosorbent assay utilized investigate peroxisome proliferator-activated receptor-alpha (PPARalpha) glucose transporter (GLUT-4) expression levels skeletal muscles, respectively. Results: found that GLUT-4 PPARalpha overexpression, together better lipid profile than alone diabetic rats. Additionally, both drugs improved C decreased creatine kinase MB isoenzyme, NF-kappaB TNF-alpha cardiac levels. Conclusion: The current indicated had effect DM. favorable exhibited upregulation receptors thus increasing insulin sensitivity improving profile. J Endocrinol Metab. 2021;11(5):140-151 doi: https://doi.org/10.14740/jem765